Syngene International Fair Value
Syngene International (SYNGENE) average fair value is ₹177.4 across 7 valuation models — P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹406.65 (-56.38%), fair value range ₹31.01–₹477.36.
Fair Value Analysis Export
SYNGENE Fair Value vs Current Price — Valuation Summary
SYNGENE average fair value, fair value range, price gap and valuation status across 7 models: P/E Based Valuation, P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit SYNGENE share price.
P/E Based Valuation
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
SYNGENE Fair Value Analysis — Data Sources & Coverage
Syngene International financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Check Syngene International market cap to track the company's total market size over time.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
SYNGENE vs Healthcare Sector Peers — P/E, P/B & Market Cap
Syngene International P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Sat Kartar Life | SATKARTAR | 12.78 | 3.19 | ₹221 |
| Jeena Sikho Lifecare | JSLL | 32.14 | 15.26 | ₹6,960 |
| SMS Lifesciences | SMSLIFE | 22.27 | 1.82 | ₹354 |
| Emcure Pharmaceuticals | EMCURE | 38.74 | 7.37 | ₹35,696 |
| Sai Life Sciences | SAILIFE | 78.41 | 11.02 | ₹26,771 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.